Arcutis Biotherapeutics ARQT
NASDAQ ARQT
$23.90 +0.24 (+1.01%)
As of: Sep 4, 2026 · 3:59 PM EDT

Arcutis Biotherapeutics (ARQT) Revenue Growth (1y) (2023 - 2026)

Analysis

Arcutis Biotherapeutics (ARQT) Revenue Growth (1y) (2023 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 12.45%
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 16.73%
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 59.71%
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 2.11%
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 29.63%
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 66.86%
8 Royalty Pharma 28.45 Bn 27.61 Bn - 16.50%
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 296.11%
10 Arcutis Biotherapeutics 3.12 Bn 2.88 Bn 118.92 Mn 59.33%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 59.33%
Mar 31, 2026 60.07%
Dec 31, 2025 81.48%
Sep 30, 2025 121.69%
Jun 30, 2025 164.13%
Mar 31, 2025 32.84%
Dec 31, 2024 427.58%
Sep 30, 2024 17.44%
Jun 30, 2024 494.57%
Mar 31, 2024 1,682.42%
Dec 31, 2023 356.81%
Sep 30, 2023 5,156.41%